Clinical Scorecard: Case Study: Efficacy of Osimertinib in HER2-Positive Ductal Carcinoma In Situ Supported by In Vitro Findings
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Patients with HER2-positive DCIS and concurrent non-small cell lung cancer (NSCLC) with EGFR mutation, specifically focusing on older female demographics.
Care Setting
Key Highlights
Osimertinib showed a marked reduction in tumor size and Ki-67 index in a patient with HER2-positive DCIS, indicating a potential therapeutic effect.
The patient had concurrent NSCLC with an EGFR mutation, treated with osimertinib post-surgery, which may have contributed to the observed outcomes.
In vitro studies indicated osimertinib's potential to inhibit HER2 activity, warranting further investigation.
Guideline-Based Recommendations
Diagnosis
Management
Standard treatment for HER2-positive DCIS includes surgical resection with or without adjuvant radiotherapy, and consideration of adjuvant therapies such as trastuzumab.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Adjuvant osimertinib therapy initiated post-surgery for NSCLC showed significant therapeutic effects on DCIS, with a detailed timeline of treatment initiation and observed effects.
Clinical Best Practices
Consider HER2 status in treatment planning for breast cancer, and monitor Ki-67 index as a marker of proliferation and treatment response, along with HER2 status for potential resistance.
